Fascination About Tyrosinase-IN-12
MI-CP151 was a phase 1b randomised, double-blind, placebo controlled, dose-escalation, multicentre analyze to evaluate numerous intravenous doses of sifalimumab, in adult patients with dermatomyositis or polymyositis (NCT00533091). Major trial objectives had been to evaluate the safety and tolerability of sifalimumab in dermatomyositis or polymyosi